Carisoprodol is indicated for:

• Relief of discomfort associated with acute, painful musculoskeletal conditions in adults
• Providing sedation and reducing anxiety in patients experiencing severe pain
• Use as an adjunct to physical therapy in the management of injuries

Carisoprodol acts as an indirect agonist at GABA-A receptors, enhancing chloride ion conductance within the central nervous system. Activation of these receptors produces sedative effects and may also contribute to anxiolytic, anticonvulsant, and muscle relaxant actions. Its active metabolite, meprobamate, possesses sedative and anxiolytic properties. Carisoprodol reduces neural transmission between the brain and spinal cord to the muscles, resulting in muscle relaxation and decreased spasm. It does not exert a direct effect on muscle fibers.

Adults (18 years and older): The recommended dose of Carisoprodol is 250 mg to 350 mg three times a day and at bedtime. The recommended maximum duration of Carisoprodol use is up to two or three weeks. Caution should be taken in patients with renal and hepatic impairment and also with reduced CYP2C19 activity.

• Caution is advised when Carisoprodol is used with other CNS depressants such as alcohol, benzodiazepines, opioids, and tricyclic antidepressants, as additive sedative effects may occur.
• Co-administration with CYP2C19 inhibitors (e.g., omeprazole, fluvoxamine) may increase Carisoprodol exposure, while CYP2C19 inducers (e.g., rifampicin) may decrease its exposure.

Carisoprodol is contraindicated in patients with a history of acute intermittent porphyria or hypersensitivity to carbamate compounds such as meprobamate.

Common adverse effects include drowsiness, dizziness, and headache.

Carisoprodol is classified as pregnancy category C. Maternal use may result in reduced effectiveness of infant feeding due to sedation and may also decrease milk production. It should be used with caution in breastfeeding women.

Due to its sedative properties, Carisoprodol may impair the ability to perform tasks requiring alertness, such as driving or operating machinery. Concurrent use with other CNS depressants, including alcohol, may enhance sedative effects. There is a risk of drug dependence, withdrawal symptoms, and abuse. Seizures have also been reported in some cases.

Overdose of Carisoprodol can lead to significant CNS depression. Reported effects include death, coma, respiratory depression, hypotension, and seizures. Management includes supportive care and monitoring of vital functions. Induced emesis is not recommended due to the risk of respiratory depression. Gastric lavage may be considered if performed within one hour of ingestion. Circulatory support with fluids and vasopressors may be required. Seizures may be treated with intravenous benzodiazepines, and recurrent seizures with phenobarbital. In severe CNS depression, airway protection with intubation may be necessary.

Locally acting Skeletal Muscle Relaxants

Store in a cool and dry place at room temperature (20°–25°C), away from direct light. Keep out of reach of children.